Investing Profile

Kush Parmar

InvestorVC

Managing Partner at 5AM Ventures

5amventures.comBoston, Massachusetts

Your Intro Paths to Kush Parmar

Signal uses Gmail to reveal intro paths. Email content is never read.

Find Kush Parmar on

Current Investing Position

5am Ventures Managing Partner

Investment Range

$100K - $5.0M

Sweet Spot

$1.5M

Investments On Record

Kush Parmar is on these Sector & Stage Rankings

Kush Parmar's Investments On Record (7)

Company	StageDateRound Size	Total Raised
Precede Biosciences	Series AOct 2023$57M	$57M
Ensoma	Series BJan 2023$85M Series AFeb 2021$70M	$210M
Co-investors: Stephen Knight (F-Prime Capital Partners), Mark Chin (Arix Bioscience), Kouki Harasaki (Bioluminescence Ventures)
Vor Biopharma	Series BJul 2020$110M Series AFeb 2019$42M	$210M
Co-investors: Reid Hoffman (Greylock)
Akouos	Series BMar 2020$110M Series AAug 2018$50M SeedNov 2017$8M	$160M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Heather Preston
Cleave Therapeutics	Series CAug 2019$12M Series BAug 2016$37M Series ANov 2011$42M	$100M
Co-investors: Robert Garland (New Enterprise Associates (NEA)), Carol Gallagher (New Enterprise Associates (NEA)), Andrew Schwab (5am Ventures), Peter Thompson (OrbiMed), Alfred Scheidegger (Nextech Invest), Marc Singer (Osage University Partners), Larry Lasky (The Column Group)
Arvinas	Series CApr 2018$55M Series BOct 2015$42M Series ASep 2013$15M	$140M
Co-investors: Colleen Cuffaro (Canaan Partners), Stephen Squinto (OrbiMed), Tim Shannon (Canaan Partners), Andrew Levin (RA Capital), Liam Ratcliffe (Access Biotechnology), Martin Alexander Gershon (Endeavor Venture Funds), Jakob Loven (Nextech Invest), Daniel Wagner (Connecticut Innovations)
Audentes Therapeutics	Series COct 2015$65M Series BDec 2014$43M Series AJul 2013$30M	$140M
Co-investors: Stephen Squinto (OrbiMed), Jonathan Silverstein (OrbiMed), Jonathan Leff (Deerfield Management), Tom Woiwode (Versant Ventures)